Key Points
- Nurix insider Gwenn Hansen sold 1,452 shares at an average price of $25.47, worth $36,982.44, under a pre-arranged Rule 10b5-1 plan. Hansen retained 117,227 shares after the transaction and has made several additional sales since June.
- NRIX shares opened at $26.04, up 1.0%, with a market capitalization of approximately $2.70 billion. The stock has climbed significantly from its 12-month low of $8.19 but remains unprofitable.
- Nurix’s latest quarterly results missed analyst expectations, with an adjusted loss of $0.81 per share versus the expected $0.73 loss and revenue of $9.04 million versus $15.29 million forecast. Despite this, analysts maintain a “Moderate Buy” consensus and an average price target of $34.21.
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 1,452 shares of the business's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $25.47, for a total value of $36,982.44. Following the completion of the sale, the insider directly owned 117,227 shares of the company's stock, valued at $2,985,771.69. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gwenn Hansen also recently made the following trade(s):
- On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $108,900.00.
- On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
- On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.
- On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $107,880.00.
Nurix Therapeutics Trading Up 1.0%
NRIX stock opened at $26.04 on Wednesday. The company has a market capitalization of $2.70 billion, a P/E ratio of -7.55 and a beta of 1.80. The business has a 50 day simple moving average of $24.65 and a 200-day simple moving average of $19.14. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $28.23.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The business had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Research analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.
Institutional Investors Weigh In On Nurix Therapeutics
Institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC increased its holdings in shares of Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company's stock valued at $29,000 after purchasing an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management purchased a new stake in Nurix Therapeutics during the fourth quarter worth about $31,000. Nykredit A S acquired a new position in Nurix Therapeutics during the second quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics during the fourth quarter worth about $33,000. Finally, KBC Group NV acquired a new position in Nurix Therapeutics during the first quarter worth about $34,000.
Analyst Ratings Changes
NRIX has been the topic of a number of research reports. Royal Bank Of Canada raised their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an "outperform" rating in a report on Monday, August 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $34.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, August 4th. Mizuho increased their price objective on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Robert W. Baird lifted their target price on Nurix Therapeutics from $26.00 to $33.00 and gave the company an "outperform" rating in a research note on Thursday, June 18th. Finally, Morgan Stanley boosted their target price on Nurix Therapeutics from $36.00 to $38.00 and gave the company an "overweight" rating in a report on Tuesday, July 28th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $34.21.
View Our Latest Research Report on Nurix Therapeutics
About Nurix Therapeutics
(
Get Free Report)
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company's pipeline includes multiple programs in various stages of development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
